公开(公告)号：US20230241223A1

公开(公告)日：2023-08-03

申请号：US17913743

申请日：2021-03-24

Applicant: BIONTECH SE

Inventor： Heinrich HAAS ,  Sara NOGUEIRA ,  Anne SCHLEGEL

IPC: A61K47/54 ,  A61K47/64 ,  A61K47/69 ,  A61K9/00

CPC classification number: A61K47/543 ,  A61K9/0019 ,  A61K47/646 ,  A61K47/6911 ,  A61K47/6929

Abstract: The present disclosure relates to RNA particles for delivery of RNA to target tissues after administration, in particular after parenteral administration such as intravenous, intramuscular, subcutaneous or intratumoral administration, and compositions comprising such RNA particles. The RNA particles in one embodiment comprise single-stranded RNA such as mRNA which encodes a peptide or protein of interest, such as a pharmaceutically active peptide or protein. The RNA is taken up by cells of a target tissue and the RNA is translated into the encoded peptide or protein, which may exhibit its physiological activity.

公开(公告)号：US20230226217A1

公开(公告)日：2023-07-20

申请号：US18071705

申请日：2022-11-30

Applicant: TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz ad ,  BioNTech SE

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Mustafa Diken ,  Daniel Fritz ,  Martin Meng ,  Lena Mareen Kranz ,  Kerstin Reuter

IPC: A61K48/00 ,  A61K39/00 ,  A61K9/127

CPC classification number: A61K48/0033 ,  A61K9/1272 ,  A61K39/0011 ,  A61K48/0025 ,  A61K2039/53 ,  A61K2039/55555

Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

公开(公告)号：US20230201817A1

公开(公告)日：2023-06-29

申请号：US18085206

申请日：2022-12-20

Applicant: BioNTech Delivery Technologies GmbH ,  BioNTech SE

Inventor： Christian Reinsch ,  David Estapé Izquierdo ,  Sierk Poetting ,  Ugur Sahin ,  Alexander Muik ,  Asaf Poran ,  Martin Lang ,  Oliver Hennig ,  Karsten Pietron-Kattmann ,  Manfred Brunen ,  Rainer Kröner ,  Mario Büttner ,  Sven Stegmann ,  Kristin Hoffmann

IPC: B01L1/00 ,  G16B30/00 ,  G16B50/30 ,  G16B20/20 ,  A61K39/215 ,  B01F25/25 ,  B01D61/14

CPC classification number: B01L1/52 ,  A61K39/215 ,  B01D61/145 ,  B01D61/147 ,  B01D61/149 ,  B01F25/25 ,  G16B20/20 ,  G16B30/00 ,  G16B50/30 ,  A61K2039/53

Abstract: A portable system for producing a formulation comprising lipid nanoparticle (LNP)-encapsulated RNA includes: a first sub-system comprising multiple drug substance formulation modules, the first sub-system comprising: a transcription module for forming an RNA solution via in vitro transcription; and a second sub-system operatively downstream of the first sub-system comprising multiple drug product formation modules, the second sub-system comprising: an LNP formulation module for producing a first RNA-LNP preparation from the RNA solution, wherein each of the transcription module and the LNP formulation module is contained within a separate standard shipping container.

公开(公告)号：US11660338B2

公开(公告)日：2023-05-30

申请号：US16749012

申请日：2020-01-22

Applicant: BIONTECH SE ,  TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES Gutenberg-Universitat Mainz Gemeinnutzige GmbH

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Yves Hüsemann ,  Mustafa Diken ,  Kerstin Reuter ,  Hossam Hefesha

IPC: A61K39/39 ,  C12N15/88 ,  A61K9/50 ,  A61K9/127 ,  A61K31/675 ,  A61K39/00

CPC classification number: A61K39/39 ,  A61K9/1271 ,  A61K9/1277 ,  A61K9/5073 ,  A61K31/675 ,  A61K39/0011 ,  C12N15/88 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/55516 ,  A61K2039/55555 ,  A61K2039/55561 ,  A61K2039/572 ,  C12N2810/10

Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.

公开(公告)号：US20230089969A1

公开(公告)日：2023-03-23

申请号：US17817033

申请日：2022-08-03

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Friederike GIESEKE ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US20230087745A1

公开(公告)日：2023-03-23

申请号：US17821837

申请日：2022-08-24

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Isil ALTINTAS ,  David SATIJN ,  Rik RADEMAKER ,  Paul PARREN ,  Ugur SAHIN ,  Friederike GIESEKE ,  Alexander MUIK ,  Christian GRUNWITZ ,  Edward VAN DEN BRINK ,  Dennis VERZIJL

IPC: C07K16/28

Abstract: The present invention relates to novel binding agents and their use in medicine. In particular, the invention relates to binding agents such as bispecific antibodies binding human PD-L1 and binding human CD137. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

公开(公告)号：US20230087164A1

公开(公告)日：2023-03-23

申请号：US17795318

申请日：2021-02-04

Applicant: GENMAB A/S ,  BIONTECH SE

Inventor： Ugur SAHIN ,  Alexander MUIK ,  Isil ALTINTAS ,  Ulf FORSSMANN ,  Kate SASSER ,  Maria JURE-KUNKEL ,  Manish GUPTA

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.

公开(公告)号：US20220313811A1

公开(公告)日：2022-10-06

申请号：US17717645

申请日：2022-04-11

Applicant: BIONTECH SE ,  TRON - TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITÄT MAINZ

Inventor： Ugur Sahin ,  Heinrich Haas ,  Annette Vogel ,  Daniel Zucker ,  Stephanie Erbar ,  Kerstin Walzer ,  Anne Schlegel ,  Sebastian Hörner ,  Sebastian Kreiter ,  Mustafa Diken ,  Jorge Moreno Herrero

IPC: A61K39/12 ,  A61K9/00 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34

Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.

公开(公告)号：US20220227756A1

公开(公告)日：2022-07-21

申请号：US17590550

申请日：2022-02-01

Applicant: BIONTECH SE

Inventor： Christophe HENRY

IPC: C07D471/04 ,  A61P35/00

Abstract: The invention relates to imidazoquinoline derivatives and to pharmaceutical compositions containing the imidazoquinoline derivatives. The imidazoquinoline derivatives of the invention are useful as toll-like receptor agonists, in particular agonists of TLR7, and promote induction of certain cytokines.

公开(公告)号：US11248264B2

公开(公告)日：2022-02-15

申请号：US16920286

申请日：2020-07-02

Applicant: TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gGmbH ,  BioNTech SE

Inventor： Ugur Sahin ,  Sebastian Kreiter ,  Mustafa Diken ,  Jan Diekmann ,  Michael Koslowski ,  Cedrik Britten ,  John Christopher Castle ,  Martin Löwer ,  Bernhard Renard ,  Tana Omokoko ,  Johannes Hendrikus De Graaf

IPC: A61K39/00 ,  C12Q1/6869 ,  G16B20/00 ,  G16B40/00 ,  C12Q1/6886 ,  G16B20/20

Abstract: The present invention relates to the provision of vaccines which are specific for a patient's tumor and are potentially useful for immunotherapy of the primary tumor as well as tumor metastases. In one aspect, the present invention relates to a method for providing an individualized cancer vaccine comprising the steps: (a) identifying cancer specific somatic mutations in a tumor specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.